1. Scrip
  2. >>Archive

INFOGRAPHIC: A US biotech IPO surge? Data are mixed

 
• By Mandy Jackson

Many people argue that the surge in initial public offerings by biotechnology companies suggests a bubble in danger of imminent explosion, but is the industry's IPO market really surging? It depends on how you interpret the numbers related to first-time stock offerings so far in 2014 versus 2015.

Many people argue that the surge in initial public offerings by biotechnology companies suggests a bubble in danger of imminent explosion, but is the industry's IPO market really surging? It depends on how you interpret the numbers related to first-time stock offerings so far in 2014 versus 2015.

On the one hand, only 29 drug developers launched IPOs in the US during the first half of this year, including 10 in June, compared with a whopping

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip